Trials / Temporarily Not Available
Temporarily Not AvailableNCT05274204
Individual Patient Expanded Access to CA102N
Expanded Access to CA102N in One Patient Who Completed at Least 12 Cycles of Combination Therapy of CA102N Plus Lonsurf in Clinical Study Number of HS-CA102N-101
- Status
- Temporarily Not Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Holy Stone Healthcare Co., Ltd · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
Detailed description
In the individual patient expanded access, the subject who was enrolled in Phase 1 trial (Study Number: HS-CA102N-101) Part 2 (dose expansion) and had completed at least 12 treatment cycles with CA102N combined with trifluridine /tipiracil (LONSURF) will be provided access to treatment with CA102N (0.72 mg/kg Nimesulide Equivalent of CA102N).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CA102N |
Timeline
- First posted
- 2022-03-10
- Last updated
- 2023-02-27
Source: ClinicalTrials.gov record NCT05274204. Inclusion in this directory is not an endorsement.